Monopar Therapeutics MNPR
Monopar Therapeutics (Nasdaq: MNPR) is a rare genetic drug developer. Its lead program, ALXN1840 (tiomolybdate choline), is in Phase 3 for Wilson disease. Its next catalyst on record is ALXN1840: Complete rolling NDA submission (FDA filing acceptance decision to follow) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ALXN1840 — Complete rolling NDA submission (FDA filing acceptance decision to follow) (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ALXN1840 | Wilson disease (pivotal Phase 3 FoCus completed by Alexion; rolling NDA initiated July 2026) | small molecule | Phase 3 |
| MNPR-101-Lu (uPAR radiotherapeutic) | advanced solid tumors | radiopharmaceutical | Phase 1 |
| MNPR-101-Zr (uPAR imaging agent) | imaging of advanced cancers | radiopharmaceutical | Phase 1 |
| MNPR-101-Ac225 | advanced cancers | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- Jul 22, 2026submitted Monopar initiated rolling NDA submission to FDA for ALXN1840 in Wilson disease and submitted the first completed sections.
Monopar has submitted the first completed sections of the NDA.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.